Nadav Pam

Rambam Health Care Campus

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ziad Khamaysi

Rambam Health Care Campus

Emily Avitan‐Hersh

Rambam Health Care Campus

Hiba Zaaroura

Rambam Health Care Campus

Khalaf Kridin

University of Lübeck

Richard N. Bergman

Cedars-Sinai Medical Center

Asheesh Gupta

Defence Institute of Physiology and Allied Sciences

Tamar Freud

Ben-Gurion University of the Negev

Magesh Sadasivam

Massachusetts General Hospital

Daniela Vecchio

Fondazione Santa Lucia

Jacob Dreiher

Clalit Health Services

Cooperative Institutions

Ben-Gurion University of the Negev

Rambam Health Care Campus

Clalit Health Services

Technion – Israel Institute of Technology

Soroka Medical Center

Tel Aviv University

Harvard University

Sheba Medical Center

Rappaport Family Institute for Research in the Medical Sciences

Massachusetts General Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa

Journal of the American Academy of Dermatology (2017)

Guy Shalom Meir Babaev Tamar Freud Shmuel Tiosano Nadav Pam

Hidradenitis Suppurativa

10.1016/j.jaad.2017.10.001

Cite

Citations (22)

Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment

Research Square (Research Square) (2023)

Ziad Khamaysi Nadav Pam Hiba Zaaroura Emily Avitan‐Hersh

Abstract Background: Infantile hemangiomas (IH) are common benign tumors of infancy. Most IH involute, either spontaneously, or secondary to pharmacological treatment with systemic propranolol. Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases. Objective: To assess the safety and efficacy of long pulsed Nd:YAG 1064 nm laser in treating patients with residual infantile hemangioma after systemic propranolol treatment. Patients and methods: This is an open-label prospective cohort study. 30 patients with focal residual IH that had sub-optimal responses to systemic propranolol treatment were enrolled in the study. The patients were treated with 1 to 3 sessions with long pulsed Nd: YAG 1064 nm laser. The maximal response of the IH was assessed using a 4-point scale evaluation scale system. Results: Of the 30 patients enrolled, 18 patients exhibited a great response (>76% improvement), 10 patients had a good response (>51-75% improvement), while only 2 patients showed a moderate response (<50% improvement) to the treatment. No patients had an unsatisfactory response. No serious side effects were observed, and only minor side effects were reported. Conclusions: The treatment with long pulsed Nd:YAG 1064 nm laser for residual IH, which were resistant to systemic propranolol treatment, is safe and effective. Thus, we suggest its use as a second-line treatment for patients with sub-optimal aesthetic results following systemic propranolol.

Infantile hemangioma

Laser Treatment

Nd:YAG laser

10.21203/rs.3.rs-2466018/v1

Cite

Citations (1)

[DERMATOLOGIC CONDITIONS IN MONOZYGOTIC TWINS].

PubMed (2020)

David Dias‐Polak Nadav Pam Ziad Khamaysi Emily Avitan‐Hersh

Genetic twin studies may shed light on the genetic basis as well as environmental and epigenetic factors in disease pathogenesis. Herein, we present four pairs of monozygotic twins sharing similar phenotypes in three dermatologic conditions, and a literature review regarding twin studies in these diseases.

Monozygotic twin

Identical twins

Pathogenesis

Source

Cite

Citations (0)

[AT THE BOTTOM OF THE ULCER - THE IMPORTANCE OF A BIOPSY IN DIAGNOSING HARD TO TREAT ULCERS].

PubMed (2020)

Sofia Raiber Nadav Pam Ziad Khamaysi Richard N. Bergman Emily Avitan‐Hersh

We report a case of a patient who presented with bilateral chronic painful necrotic leg ulcers. A skin biopsy revealed histopathological findings compatible with calciphylaxis, a rare phenomenon accompanied by high morbidity and mortality. Treatment options are limited and are based mainly on case reports and small series, so further research is needed in this area. This case highlights the importance of a skin biopsy in the diagnosis of chronic ulcers.

Calciphylaxis

Skin biopsy

Skin ulcer

Source

Cite

Citations (0)

Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.

PubMed (2013)

Pinar Avci Asheesh Gupta Magesh Sadasivam Daniela Vecchio Zeev Pam

Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function. Although skin is naturally exposed to light more than any other organ, it still responds well to red and near-infrared wavelengths. The photons are absorbed by mitochondrial chromophores in skin cells. Consequently, electron transport, adenosine triphosphate nitric oxide release, blood flow, reactive oxygen species increase, and diverse signaling pathways are activated. Stem cells can be activated, allowing increased tissue repair and healing. In dermatology, LLLT has beneficial effects on wrinkles, acne scars, hypertrophic scars, and healing of burns. LLLT can reduce UV damage both as a treatment and as a prophylactic measure. In pigmentary disorders such as vitiligo, LLLT can increase pigmentation by stimulating melanocyte proliferation and reduce depigmentation by inhibiting autoimmunity. Inflammatory diseases such as psoriasis and acne can also be managed. The noninvasive nature and almost complete absence of side effects encourage further testing in dermatology.

Vitiligo

Light therapy

Skin repair

Depigmentation

Source

Cite

Citations (481)

Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth

Dermatologic Therapy (2021)

Nadav Pam Khalaf Kridin Ziad Khamaysi

Propranolol emerged as the first-line therapy for infantile hemangioma (IH). Determinants of interindividual variation in drug response and predictors of rebound growth after drug discontinuation are yet to be firmly established. We aimed to evaluate the outcomes of a relatively large cohort of patients with IH treated by propranolol and to determine predictors of (a) an excellent response to treatment (≥90 improvement) and (b) of rebound growth after drug cessation. A retrospective cohort study was conducted to follow all patients with IH receiving systemic propranolol in a referral center-based specialized clinic. Multivariate logistic regression analysis was performed to identify predictors of excellent response and rebound growth. The study included 206 patients who completed oral propranolol treatment. The mean (SD) age in which the drug was initiated was 4.8 (3.1) months. The average improvement rate was estimated at 85.5 (13.8)%. Initiation of propranolol at the age of 0 to 3 (adjusted odds ratio [OR], 3.43; 95% confidence interval [CI], 1.25-9.40; P = .016) and 3 to 6 (adjusted OR, 3.71; 95% CI, 1.50-9.19; P = .005) months was associated with an increased likelihood of excellent response. Twenty-four (11.7%) patients developed rebound growth following cessation of propranolol. No significant predictors of rebound were identified in the multivariate analysis. Eleven (5.3%) patients experienced mild adverse events, which necessitated drug discontinuation in only two (1.0%) patients. Propranolol is highly effective and safe based on the real-life experience of a referral center for IH. The current study supports early initiation of propranolol.

Discontinuation

Infantile hemangioma

10.1111/dth.14936

Cite

Citations (20)

Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study

Dermatologic Therapy (2020)

Khalaf Kridin Nadav Pam Richard N. Bergman Ziad Khamaysi

The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase. Evaluation of the effectiveness of oral propranolol is less established when it is administered in late infancy following the proliferative phase. We aimed to assess the clinical outcomes of pediatric patients managed by oral propranolol beyond the proliferative phase of IH. A retrospective cohort study in a tertiary health care referral center was conducted to track all patients with IH receiving systemic propranolol following the proliferative phase. Twenty-eight eligible patients were managed by 2 to 3 mg/kg per day of oral propranolol for IH beyond the proliferative phase, defined at 9 months of age. The mean age at the initiation of propranolol was estimated at 11.25 (SD 2.24) months. All eligible patients experienced some degree of clinical resolution, with the average improvement rate being estimated at 77.1% (SD 16.1). Comparable results were achieved among patients who were placed on propranolol at an age older than 12 months and those managed between the age of 9 and 12 months. No serious adverse events were observed during the follow-up duration. In conclusion, oral propranolol is a safe and effective treatment for patients with IH initiating this agent beyond the proliferative phase.

Infantile hemangioma

10.1111/dth.13331

Cite

Citations (14)

Mechanisms of action and medical evidences of the therapeutic effect of oral gelatin on telogen effluvium and androgenetic alopecia in both men and women

Surgery Current Research (2012)

Nadav Pam

Gelatin

10.4172/2161-1076.s1.005

Cite

Citations (0)

Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment

Scientific Reports (2023)

Ziad Khamaysi Nadav Pam Hiba Zaaroura Emily Avitan‐Hersh

Abstract Infantile hemangiomas (IH) are common benign tumors of infancy. Most IH involute, either spontaneously, or secondary to pharmacological treatment with systemic propranolol. Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases. To assess the safety and efficacy of long pulsed Nd:YAG 1064 nm laser in treating patients with residual infantile hemangioma after systemic propranolol treatment. This is an open-label prospective cohort study. 30 patients with focal residual IH that had sub-optimal responses to systemic propranolol treatment were enrolled in the study. The patients were treated with 1 to 3 sessions with long pulsed Nd:YAG 1064 nm laser. The maximal response of the IH was assessed using a 4-point scale evaluation scale system. Of the 30 patients enrolled, 18 patients exhibited a great response (> 76% improvement), 10 patients had a good response (> 51–75% improvement), while only 2 patients showed a moderate response (< 50% improvement) to the treatment. No patients had an unsatisfactory response. No serious side effects were observed, and only minor side effects were reported. The treatment with long pulsed Nd:YAG 1064 nm laser for residual IH, which were resistant to systemic propranolol treatment, is safe and effective. Thus, we suggest its use as a second-line treatment for patients with sub-optimal aesthetic results following systemic propranolol.

Infantile hemangioma

Laser Treatment

Nd:YAG laser

10.1038/s41598-023-33870-0

Cite

Citations (5)